AbbVie Earnings Preview: What To Expect February 4, 2026

AbbVie reports fourth quarter 2025 results on February 4 before market open. The quarter provides the first clean read on whether the company’s adjusted EPS trajectory has stabilized after a year dominated by acquired IPR&D charges that repeatedly reset full-year guidance. Consensus sits at $1.78 EPS on $15.58B revenue, but management pre-framed Q4 adjusted EPS at $2.61 to $2.65 midpoint after flagging another acquired IPR&D expense item in early January.

The setup creates a measurement problem. Street estimates reflect the company’s historical beat pattern (83.3% beat rate over the last 20 quarters), yet management’s pre-announced guidance already incorporates the Q4 charge, making the traditional consensus comparison less informative than the gap between reported results and the $2.63 midpoint. The stock trades at a 172x trailing P/E, a multiple distorted by 2025’s episodic charges rather than reflective of core profitability. Forward estimates price AbbVie at 15.9x 2026 EPS, a 12% discount to the peer group median of 18.1x, suggesting the market has not yet fully re-rated the shares for a cleaner earnings path.

What the quarter will determine is whether AbbVie can articulate a 2026 framework in which adjusted EPS grows without the volatility of deal-related accounting hits, and whether the Skyrizi and Rinvoq growth engines can offset both the ongoing Humira erosion and the Q3 2025 aesthetics softness that drove a 4% post-earnings decline despite a revenue beat. The ability to provide credible full-year 2026 guidance with minimal specified items will matter more for the stock’s re-rating than whether Q4 clears a pre-set bar by a few cents.

Consensus Estimates

The disconnect between Street consensus ($1.78) and management’s Q4 adjusted EPS midpoint ($2.63) reflects how acquired IPR&D charges have fragmented the estimate framework. AbbVie’s January 7 update explicitly incorporated a Q4 charge into the $2.61 to $2.65 range, yet consensus has not converged to that band, likely because analysts are modeling “core” profitability rather than management’s adjusted definition. The 47.7% gap ($1.78 vs $2.63) is the widest estimate divergence AbbVie has faced in the past five years.

Revenue consensus at $15.58B sits 7.8% above prior year, consistent with the Skyrizi and Rinvoq growth trajectory that has offset Humira’s decline in each of the last four quarters. The estimate range is narrow (320 basis points from low to high), indicating Street confidence in top-line visibility. The risk lies in whether consensus has adequately modeled aesthetics segment weakness after Q3’s miss, when Reuters tied the stock’s 4% decline to softness in Botox-related categories despite an overall revenue beat.

Management Guidance and Commentary

“We expect acquired in-process research and development, or IPR&D, and milestone expense in the fourth quarter of 2025. As a result, we are updating our 2025 adjusted diluted earnings per share guidance to a range of $10.61 to $10.65.”

AbbVie’s January 7 update formalized what had been telegraphed in October: another quarter with deal-related charges folded into the adjusted EPS framework. The company raised its full-year 2025 adjusted EPS range to $10.61 to $10.65 from the prior $10.38 to $10.58, a 23-cent midpoint increase that still sits 14.4% below the $12.22 midpoint issued in January 2025. The revision history underscores the challenge investors face in modeling “adjusted” profitability when the definition shifts with acquisition timing.

Management’s Q4 adjusted EPS guidance of $2.61 to $2.65 (midpoint $2.63) creates a 47.7% premium to Street consensus at $1.78, the widest gap in recent history. This divergence stems from how AbbVie defines adjusted EPS versus how analysts model core earnings, a framing issue that has persisted throughout 2025. The company has consistently excluded acquired IPR&D from adjusted figures while the Street has taken a more conservative approach, leading to mechanical beats on management’s terms but questions about earnings quality.

Analyst Price Targets & Ratings

Wall Street maintains a constructive view with 80% of analysts rating shares a Buy or Strong Buy. The consensus target of $245.04 implies 8.6% upside from current levels, though the target range reflects varying assumptions about how quickly AbbVie can normalize earnings and expand margins in the post-Humira era.

Sector & Peer Comparison

AbbVie trades at a 172.3x trailing P/E, an outlier driven by 2025’s episodic charges rather than a sustainable valuation framework. The forward P/E of 15.9x provides a more relevant comparison, positioning AbbVie at a 12% discount to the peer group median of 18.1x. This discount reflects investor skepticism about earnings quality given the year’s IPR&D volatility, despite the company’s 4.0% profit margin sitting well below peers like Amgen (28.3%) and Merck (21.4%).

Earnings Track Record

AbbVie’s 83.3% beat rate over the last 20 quarters establishes a pattern of consistent execution, yet the Q3 2025 miss stands out as an inflection point. The 43.1% shortfall ($1.86 vs $3.27) was the largest negative surprise in the company’s recent history, driven entirely by how acquired IPR&D charges were incorporated into the adjusted EPS definition rather than operational underperformance.

Post-Earnings Price Movement History

The post-earnings movement pattern reveals a counterintuitive dynamic: the largest positive reaction (+9.5%) followed the largest negative surprise (Q3 2025’s 43.1% miss). This inversion occurred because the market looked through the accounting-driven EPS shortfall to focus on the 1.2% revenue beat and management’s guidance raise. The reaction demonstrates that investors now prioritize forward visibility and segment performance over mechanical beats on adjusted EPS.

Expected Move & Implied Volatility

The options market prices a 3.8% move in either direction, translating to a range of $217.08 to $234.24. This expected move sits above the historical average next-day reaction of 2.8% but below the 9.5% move that followed Q3 2025’s accounting-driven miss. The elevated implied move reflects uncertainty about whether Q4 will provide the clean 2026 framework investors are seeking.

Expert Predictions & What to Watch

Key Outlook: Guidance Will Drive the Trade

The base case assumes AbbVie prints adjusted EPS between $2.61 and $2.70, clearing the management-guided range while demonstrating that Q4 execution remained on track despite the aesthetics headwinds flagged in Q3. Revenue should land between $15.5B and $15.8B, supported by immunology franchise growth that offsets Humira’s ongoing erosion.

Key Metrics to Watch

The Skyrizi and Rinvoq growth rate will provide the clearest read on whether AbbVie’s post-Humira thesis remains intact. Consensus expects these franchises to grow revenue by approximately 20% year-over-year in Q4, consistent with the trajectory that has offset Humira’s decline in recent quarters. Growth below 15% would raise concerns about competitive pressure, while growth above 25% would reinforce the bull case that these assets can drive sustainable double-digit top-line expansion through 2027.

Operating margin trajectory matters because it determines whether AbbVie can re-rate toward peer multiples. The current 35.5% operating margin sits 200 to 300 basis points below the peer group median, a gap that reflects both Humira’s high-margin erosion and the R&D intensity of the current portfolio build. Management’s ability to articulate a credible path to 37% or higher operating margins by 2026 would support multiple expansion independent of earnings beats.